Ensysce Biosciences Invited to Participate in Upcoming Scientific and Industry Events

~ Company leadership to highlight TAAP and MPAR programs, discuss innovation in pain therapeutics and present on commercial excellence ~

SAN DIEGO, CALIFORNIA / ACCESS Newswire / February 23, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (“Ensysce” or the “Company”), a clinical-stage pharmaceutical company developing innovative solutions for novel therapeutics while reducing the potential for abuse and overdose, today announced that members of its executive management team including Dr. Lynn Kirkpatrick, Dr. William Schmidt and Mr. Geoff Birkett have been invited to participate in upcoming scientific and industry events focused on next-generation pain therapeutics, substance use disorder research and commercial best practice.

U.S. Association for the Study of Pain (USASP) Annual Scientific Meeting

• March 23-26, 2026

• Philadelphia, PA

• Dr. William Schmidt to present in session: Innovations in Pain Therapeutics: Translating Novel Mechanisms into Real-World Relief

First-ever European Pain Therapeutics Summit

• May 7-8, 2026

• Amsterdam, Netherlands

• European-focused clinical development, regulatory perspectives and EU-based biotech, pharma, and academic innovation in pain therapeutics

• Dr. Lynn Kirkpatrick to present emerging data on PF614 and PF614-MPAR

Commercial Excellence and AI – Immersion Lab.

• June 3-4, 2026

• Philadelphia, PA

• Mr. Geoff Birkett to lead discussions on commercial/launch excellence

The College on Problems of Drug Dependence (CPDD) 88^th Annual Meeting

• June 13-17, 2026

• Portland, OR

Dr. Lynn Kirkpatrick to present in NIDA-Supported Substance Use Disorders Therapeutics Development Research – Overview and Highlights Symposium

Throughout these events Ensysce has been asked to provide updates on its technology platforms and highlight their novelty while discussing the development strategy for both PF614 and PF614-MPAR. More commercial discussion will involve overviews on portfolio management, branding and value building.

“These engagements provide important opportunities to engage with the clinical, scientific, and industry communities and to highlight Ensysce’s differentiated approach to developing innovative therapeutics with the potential to reduce abuse and overdose risk,” said Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce Biosciences. “We look forward to sharing updates across our development programs and participating in important discussions focused on advancing safer, evidence-based innovation.”

About Ensysce Biosciences

Ensysce Biosciences is a clinical-stage pharmaceutical company dedicated to disrupting the analgesic landscape through the development of a new class of safer opioid medicines for the treatment of severe pain. Leveraging its proprietary Trypsin-Activated Abuse Protection (TAAP™) and Multi-Pill Abuse Resistance (MPAR®) platforms, Ensysce is advancing tamper-resistant therapeutic options designed to minimize the risk of opioid abuse and oral overdose while preserving strong analgesic efficacy. For more information, visit www.ensysce.com.

Forward-Looking Statements

Statements contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of words such as “may,” “intends,” “can,” “might,” “will,” “expect,” “plan,” “possible,” “believe” and other similar expressions are intended to identify forward-looking statements. The product candidates discussed are in clinic and not approved and there can be no assurance that the clinical programs will be successful in demonstrating safety and/or efficacy, that Ensysce will not encounter problems or delays in clinical development, or that any product candidate will ever receive regulatory approval or be successfully commercialized. All forward-looking statements are based on estimates and assumptions by Ensysce’s management that, although Ensysce believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Ensysce expected. In addition, Ensysce’s business is subject to additional risks and uncertainties, including among others, the initiation and conduct of preclinical studies and clinical trials; the timing and availability of data from preclinical studies and clinical trials; expectations for regulatory submissions and approvals; potential safety concerns related to, or efficacy of, Ensysce’s product candidates; the availability or commercial potential of product candidates; the ability of Ensysce to fund its continued operations, including its planned clinical trials; the dilutive effect of stock issuances from our fundraising; and Ensysce’s and its partners’ ability to perform under their license, collaboration and manufacturing arrangements. These statements are also subject to a number of material risks and uncertainties that are described in Ensysce’s most recent quarterly report on Form 10-Q and current reports on Form 8-K, which are available, free of charge, at the SEC’s website at www.sec.gov. Any forward-looking statement speaks only as of the date on which it was made. Ensysce undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required under applicable law.

Ensysce Biosciences Company Contact:

Lynn Kirkpatrick, Ph.D.
Chief Executive Officer
(858) 263-4196

Ensysce Biosciences Investor Relations Contact:

Shannon Devine
MZ North America
Main: 203-741-8811
ENSC@mzgroup.us

SOURCE: Ensysce Biosciences Inc.

View the original press release on ACCESS Newswire